Drugs / JKN2403
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07351734 | Nov 2025 → Sep 2026 overdue | chronic obstructive pulmonary disease | Joincare Pharmaceutical Group Industry Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JKN2403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07351734 ↗ |
| Route | Oral | “JKN2403 Tablets once daily orally” NCT07351734 ↗ |